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Antiphospholipid syndrome was first described 27 years ago in patients with systemic lupus erythematosus (SLE) and positive anticardiolipin antibodies, who presented with a clotting syndrome that affected arteries and veins. 1 Female patients had a high risk of recurrent miscarriage and late fetal loss. The international classification criteria for this syndrome used today are based on those initial clinical observations.
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The syndrome is under-recognised and underdiagnosed and can have devastating consequences if untreated, mainly because of uncontrolled thrombosis. Difficulties in diagnosis are compounded by a lack of standardisation of diagnostic tests. Early recognition is crucial, because treatment can reduce mortality and morbidity in relatively young people who often present with diseases such as stroke, myocardial infarction, and deep vein thro mbosis.
Because of its variable clinical presentation, patients with antiphospholipid syndrome present to a variety of medical practitioners. Here, we introduce this complicated and intriguing syndrome, and provide basic guiding principles for the recognition, diagnosis, and management of affected patients.
what is antiphospholipid syndrome?
Antiphospholipid syndrome is a systemic autoimmune disorder characterised by arterial and venous thrombosis, adverse outcomes in pregnancy (for mother and fetus), and raised titres of antiphospholipid antibodies. It occurs in isolation (primary antiphospholipid sy ndrome) in more than 50% of patients, but it can be associated with other autoimmune diseases. SLE is the
SummaRy pointS
If untreated, antiphospholipid syndrome can lead to permanent disability, severe maternal or perinatal morbidity, or even death Symptoms can occur in virtually all organ systems Venous thrombosis and stroke are the most common thrombotic manifestations In pregnancy the syndrome is associated with adverse maternal and fetal outcomes The lupus anticoagulant test is the most useful because positivity correlates most strongly with clinical manifestations Cardiac valvular disease is an important clinical manifestation and may contribute to the risk of stroke most c ommon-20-35% of patients with SLE develop secondary antiphospholipid syndrome. 3 An acute variant of the syndrome-catastrophic antiphospholipid syndrome-results in widespread thrombotic microangiopathy and multiple organ failure (box 1). 4 Classification criteria were last updated in 2006 (box 2). A combination of clinical and laboratory findings is needed to confirm the diagnosis.
2
Box 1 | Catastrophic antiphospholipid syndrome Catastrophic antiphospholipid syndrome is a rare life threatening condition, characterised by the rapid development of multiple microthrombi in various organ systems, typically the brain ( fig 1A) , kidneys ( fig 1B) , lungs, and skin.
w1 Thrombocytopenia, haemolysis, schistocytes ( fig 1C) and activation of the coagulation system are common laboratory findings, so thrombotic thrombocytopenic purpura, haemolytic uraemic syndrome, and disseminated intravascular coagulation are important differential diagnoses. Mortality in this syndrome approaches 50%. Data on treatment are limited, but current treatment regimens have reduced mortality when compared with historical case series.
w2 Successful treatment regimens include anticoagulation, high dose corticosteroids, and plasma exchange, with or without intravenous immunoglobulins. Plasma exchange seems to be particularly useful in thrombotic microangiopathy. Precipitating disorders such as infection should be treated promptly.
SOURCES AND SELECTION CRITERIA
We searched the following databases for evidence from systematic reviews, clinical trials, and prospective cohort studies: PubMed (1949 to January 2010), Embase (1980 to January 2010), Web of Science (1945 to January 2010), Cochrane Library (1990 to January 2010), CINAHL (1982 to January 2010), and Academic Search Premier (1865 to January 2010). All relevant keyword variations were used. In general, the search consisted of the combination of the following terms: "antiphospholipid syndrome", "Hughes syndrome", "antiphospholipid antibodies", "lupus anticoagulant", "anticardiolipin antibodies", "anti-β 2 glycoprotein I antibodies", and "catastrophic antiphospholipid syndrome". Results were limited to articles written in English.
CliniCal Review who gets it?
SLE affects one to 20 in every 100 000 women (depending on ethnic origin), and around 30% of those develop secondary antiphospholipid syndrome. The population prevalence of primary antiphospholipid syndrome is unknown, although it is estimated that it affects 0.5% of the population.
Antiphopholipid syndrome occurs mainly in young women of fertile age, rarely occurs in children, and only 12% of patients present after age 50. In a large international cohort, mean age at diagnosis was 34 (standard deviation 13) years. The male:female ratio was 1:3.5 for primary disease and 1:7 for secondary diagnosis associated with SLE.
3 A recently reported, unique cohort of 122 paediatric cases (primary and secondary) had a mean age of 10.7 at disease onset (range 1.0-17.9) and a male:female ratio of almost 1:1.
7 Patients who present after 50 are more often male and present more often with stroke and coronary heart disease.
2 Fewer than 1% of patients with primary or secondary antiphospholipid syndrome develop the catastrophic form, and in almost half of them it appears de novo, without previous thrombotic events.
3 what are antiphospholipid antibodies and how might they cause symptoms? Antiphospholipid antibodies form a heterogeneous group of autoantibodies directed at plasma proteins that bind to phospholipids. 8 Some antibodies from the antiphospholipid family have a paradoxical effect on coagulation: in vivo they are associated with recurrent thrombosis, but in vitro they increase phospholipid dependent clotting times, a phenomenon known as "lupus anticoagulant" activity.
w3 The "lupus anticoagulant assay" is a functional assay based on a combination of several clotting tests. Two other antibodies are useful for diagnosing antiphospholipid syndrome: anticardiolipin antibodies and anti-β 2 glycoprotein I antibodies (box 1), 2 both of which can be detected by enzyme linked immunosorbent assays (ELISAs).
Antibodies with lupus anticoagulant activity are important clinically-two systematic reviews found them to be strongly correlated with thrombotic and obstetric complications of the syndrome.
9 10 Table 1 describes assays for lupus anticoagulant, anticardiolipin antibodies, and anti-β 2 glycoprotein I antibodies.
Unfortunately, agreement between laboratories for all of these assays is poor. A recent survey that evaluated lupus anticoagulant positive plasma samples found a false positive rate of 24%.
w4 This highlights the importance of good communication between the laboratory and the clinician when making a diagnosis and of ensuring that guidelines are followed.
5
Antiphospholipid antibodies are found in 1-5% of apparently healthy subjects. Prevalence increases with age and may be influenced by chronic disease, infections, malignancies, and the use of certain drugs. Positivity in these conditions usually arises from IgM antibodies at low titres and is not associated with thrombosis or adverse pregnancy outcome.
11 Persistent positivity is rare. In a cross sectional study of 552 healthy blood donors, 6.5% had anticardiolipin IgG, but fewer than 2% still had increased titres nine months later.
w5 A definitive diagnosis of antiphospholipid syndrome requires the presence of clinical criteria and positive results for at least one of the three assays on at least two separate occasions 12 weeks apart because only persistent antiphospholipid antibodies are clinically relevant.
w6
The correlation between current antiphospholipid antibody and clinical symptoms is variable. Well designed prospective diagnostic studies are scarce. Difficulties in interpreting clinical-serological studies arise from nonstandardised assays, variable inclusion criteria, and broad definitions for case selection. Overall, the evidence supports the following:
• Lupus anticoagulant is strongly associated with venous thrombosis, in SLE and in the general population (odds ratio 11). 9 This effect is stronger in younger age groups (<50).
w7
• Lupus anticoagulant is strongly associated with stroke, in SLE and the general population (odds ratio 8.1, 95% confidence interval 2.4 to 27.5). This effect is stronger in young age groups (<50). 
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• Lupus anticoagulant is strongly associated with fetal loss at greater than 10 weeks' gestation (7.8, 2.30 to 26.45).
10
• Lupus anticoagulant predicts venous thrombosis and fetal loss more strongly than do anticardiolipin antibodies (odds ratio 1.6-3.5).
9 10
• The anticardiolipin ELISA is thought to have high sensitivity but low specificity. A positive result has a stronger association with morbidity in pregnancy than with thrombosis.
10 w10 w11
• Studies that have investigated the relation between anti-β 2 glycoprotein I antibodies and clinical symptoms have shown contradictory findings. 10 w6 w12 The clinical relevance of isolated anti-β 2 glycoprotein I antibodies is uncertain.
• Patients with positivity for all three antibodies have a particularly high risk for pregnancy morbidity or thromboembolism (34.4, 3.5 to 335).
w13 w14
• Risk factors for thrombosis such as smoking (arterial disease) and oral contraception (venous thrombosis) further increase the risk of thrombosis in the presence of antiphospholipid antibodies.
w8
• The risk of apparently healthy people with persistently positive antiphospholipid antibodies eventually developing a clinical event, such as thrombosis or adverse pregnancy outcome, is unknown.
what is known about its aetiology and pathophysiology?
The cause of the production of autoantibodies to phospholipid binding proteins such as anti-β 2 glycoprotein I is largely unknown. 8 12 effect on coagulation and inflammatory pathways Antiphospholipid antibodies affect the coagulation cascade and inflammation. In a process mediated by β 2 glycoprotein I, antiphospholipid antibodies bind to platelets and endothelial cells, activating endothelial cells and inducing a procoagulant state. Antibody binding also activates complement, w15 resulting in recruitment of other inflammatory cells, activation of tissue factor, endothelial damage, and finally thrombosis.
w16 Although cerebral involvement is thought to be mainly thrombotic in nature, evidence now suggests that antiphospholipid antibodies may have more direct effects, causing neurological impairment unrelated to thrombosis through antibody-cellular interactions, possibly because of complement activation w17 or a disrupted blood-brain barrier.
w18 w19
Is there an additional trigger? Most patients develop a discrete thrombotic event at a certain site in the body, suggesting that an additional trigger or risk factor-a "second hit"-is needed for the development of thrombosis. Infection, local endothelial damage, and pregnancy are possible candidates.
Pregnancy
Thrombosis in the placental vasculature was initially thought to be the main cause of adverse outcomes in pregnancy. However, placental thrombosis and infarction are not specific to antiphospholipid syndrome but occur in other conditions, such as non-antiphospholipid syndrome pre-eclampsia. w20 In vitro and animal studies showing that antiphospholipid antibodies can bind directly to trophoblast cells and cause direct cellular injury, defective invasiveness, and a local inflammatory response as a result of activation of the classical and alternative pathways of complement provided important insights into the pathophysiology of pregnancy loss.
w16 w21 Moreover, they showed that the protective effect of heparin resulted from its anti-complement activity and not only from its effects on coagulation.
w22 Antiphospholipid antibodies seem to cause direct dysfunction of the trophoblast as well as activation A PATIENT'S PERSPECTIVE From the age of 16, I had frequent headaches, sometimes with double vision, and I occasionally had pins and needles in one hand. My general practitioner never found an obvious cause. At 21 I was diagnosed with a deep vein thrombosis in my left leg, after a minor car accident. I was treated with heparin and aspirin for a few months. A year later I had a miscarriage at 9 weeks' gestation. My platelets were low and did not improve. My gynaecologist sent me to a haematologist, who thought of the antiphospholipid syndrome. The blood test was positive. It was a double feeling: on the one hand I felt relieved to have a diagnosis that explained all my medical problems, but I suddenly had a disease that I had never heard of. My friends and family have difficulty understanding when I try to explain what antiphospholipid syndrome is. The most frustrating thing is that even some of the doctors I talk to have never heard of it. Two years ago they found out that two of my heart valves are leaking. I have had surgery for one valve recently, and one more operation is needed for the other. It is scary to think that if my anticoagulation therapy is stopped I will be at risk of developing things like a stroke. It is surreal to have to think about these things in your early 30s. Because of the heart valves I had to postpone further pregnancies. I hope for the best, and hope that with heparin treatment I'll have a fair chance of becoming a mother one day.
A Meijer-Bezema, Stadskanaal, Netherlands
CliniCal Review of complement at the fetomaternal interface, resulting in an impaired exchange of blood components between mother and fetus, which can lead to early miscarriage, pre-eclampsia, intrauterine growth restriction, or even intrauterine fetal death.
How do patients with antiphospholipid syndrome present?
The clinical features of antiphospholipid syndrome are diverse and can affect all organ systems. Figure 2 gives an overview of the most common clinical findings. Venous thrombosis, along with its complications, is more common than arterial thrombosis. In a cohort of 1000 patients, the first symptom was deep vein thrombosis in the leg in 32% and pulmonary embolism in 14%. 3 Other vessels such as renal, hepatic, subclavian, and retinal veins; cerebral sinuses; and vena cava are more often affected than in thrombosis not related to antiphospholipid syndrome. 3 The most common arterial thrombotic events are stroke and transient ischaemic attack, which are the initial clinical manifestation in 13% and in 7% of patients, respectively.
3
Recurrent thrombotic events are common. The vascular pattern of recurrent thrombosis is fairly consistent for venous thrombosis (70% venous recurrence) and arterial thrombosis (90% arterial recurrence).
w23
Cerebral involvement Cerebral involvement is common in antiphospholipid syndrome and was highlighted in the original description of the syndrome.
1 w24 Cerebral ischaemia, migraine, cognitive dysfunction, seizures, chorea, transverse myelitis, psychosis, depression, and Guillain-Barré syndrome have all been associated with the presence of antiphospholipid antibodies.
w19 Despite a strong observed association between chronic headache, including migraine, and antiphospholipid syndrome, w25 studies have shown contradictory results. w26 An association has been reported between valvular heart disease and central nervous system manifestations of the syndrome, which suggests that c erebral emboli from valvular lesions may be a risk. 
Involvement of other organs
The most common cardiac abnormality in patients with antiphospholipid syndrome is non-bacterial thrombotic endocarditis characterised by adherent platelet-fibrin thrombi on the endocardial surface of valves, which has been reported in 11.6% of patients during the evolution of disease.
3 w28 Myocardial infarction is the presenting symptom of the syndrome in 2.8% of patients. Thrombosis can occur anywhere in the renal vasculature. Occlusion of the renal veins and arterial trunk can occur, and microthrombi in glomerular capillaries can cause rapid decline of renal function. 3 In secondary antiphospholipid syndrome, no prospective studies have looked at whether antiphospholipid antibodies worsen the outcome for traditional lupus, but retrospective analyses provide good evidence for this.
w29
Haematological manifestations, such as thrombocytopenia and haemolytic anaemia, and dermal symptoms, such as livedo reticularis, occur in 10-30% of patients, although these features are not included in the classification criteria.
3 Box 3 lists red flag and yellow flag conditions that indicate when antiphospholipid syndrome should be included in a differential diagnosis.
Maternal and fetal effects in pregnancy
Obstetric criteria used to define antiphospholipid syndrome are fetal loss after 10 weeks' gestation, three or more unexplained consecutive embryonic losses before the 10th week of gestation, and pre-eclampsia or features of placental insufficiency associated with the premature birth of a morphologically normal neonate before the 34th week of gestation.
3 Other manifestations that are not stated in the criteria, but are sequelae of the syndrome, are pregnancy related maternal thrombosis and unexplained intrauterine growth restriction.
Late fetal loss is strongly associated with the presence of antiphospholipid antibodies, particularly lupus anticoagulant. Prospective studies have shown that positive lupus anticoagulant or high titres of cardiolipin IgG increase the risk of recurrent adverse outcome in a subsequent pregnancy. Evidence for a causal association between antiphospholipid antibodies and early miscarriage is limited.
10
Early miscarriage is relatively common and has many causes, of which fetal chromosomal abnormalities are the most likely. Observational studies of the association between antiphospholipid syndrome and recurrent early miscarriage are likely to be heavily confounded, especially by inclusion of women with sporadic rather than recurrent miscarriage. International guidelines therefore advise screening for antiphospholipid an tibodies only in women with more than three early miscarriages.
14
Women with antiphospholipid syndrome have an increased incidence of early or severe pre-eclampsia, which often leads to iatrogenic preterm birth due to termination of pregnancy for maternal or fetal reasons. Preeclampsia with severe thrombocytopenia may also point towards the presence of the syndrome, and is a red flag condition (box 3). 
Systemic lupus erythematosus
Testing for antiphospholipid antibodies is recommended in the initial evaluation of patients with SLE and should be re-evaluated if new risk factors for thromboembolic events emerge. 17 Lupus anticoagulant and persistent anticardiolipin antibodies increase the risk of thromboembolic events in patients with SLE. w32 w33 Data on antiphospholipid antibodies can help when interpreting new symptoms in these patients and may influence therapeutic decisions in situations with increased thromboembolic risk, such as surgery, pregnancy, puerperium, or the use of oestrogen containing drugs.
Pregnancy
A recent prospective study of pregnant women with only one previous spontaneous abortion before the 10th week of gestation reported that the presence of antiphospholipid antibodies significantly increased the risk of embryonic loss, pre-eclampsia, and intrauterine growth restriction in the next pregnancy.
w30 However, after single pregnancy loss, most subsequent pregnancies are u neventful without treatment. Therefore, testing after one early miscarriage, or even testing all women who plan to become pregnant, is not advised.
16
How can antiphospholipid syndrome be treated? Antithrombotic agents aim to reduce the risk of recurrent thromboembolism and are the mainstay of treatment.
ONGOING RESEARCH AND FUTURE CHALLENGES
To clarify the relation between inflammation and thrombosis in antiphospholipid 
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Recent guidelines on treating the syndrome subdivide patients into those with venous thrombosis, those with arterial thrombosis, and those with obstetric antiphospholipid syndrome.
18 Figure 3 shows a treatment algorithm containing an overview of these guidelines.
First episode
For a first episode of unprovoked venous thrombosis or thromboembolism associated with persistent positive antiphospholipid antibodies, long term anticoagulation with vitamin K antagonists, such as warfarin, is recommended to reduce the risk of recurrence of a thrombotic event. 19 However, if a reversible risk factor for thr omboembolism-such as surgery, immobilisation, oestrogen therapy, or pregnancy-is reliably eliminated indefinite anticoagulation may not be justified.
18
The only prospective study focusing on arterial cerebral events showed similar rates of recurrent thromboembolism and risk of major bleeding in patients treated with warfarin or low dose aspirin. 20 However, inappropriate criteria for defining antiphospholipid antibody positivity limit the generalisability of this study. 21 In patients with antiphospholipid syndrome and stroke, long term anticoagulation with warfarin or low dose aspirin is advised.
Two randomised controlled trials compared high intensity anticoagulation (aimed at an international normalised ratio (INR) of 3.1-4) with moderate intensity anticoagulation (INR 2-3) for the prevention of recurrent venous and arterial thrombotic events in non-pregnant adults with antiphospholipid syndrome. Both trials used oral warfarin and found that high intensity treatment was no better at preventing thrombotic events. 22 23 When results were pooled, the risk of bleeding was slightly increased in patients on high intensity treatment. w34 The limitations of these trials (patients with arterial events were in the minority and many patients randomised to a target INR >3 did not achieve this target), and the fact that the results contradict those of observational st udies, mean that treatment aims are still a point of ongoing debate. 21 International guidelines and systematic reviews currently recommend aiming for an INR between 2 and 3. 18 19 24 25 Preventing obstetric complications Several strategies have been proposed to prevent maternal thrombotic complications and improve the outcome of pregnancy in women with antiphospholipid syndrome. Few well designed trials have been carried out and studied populations are heterogeneous, so the level of evidence for all treatment options is low. Table 2 gives suggestions for primary and secondary prevention of thrombosis and adverse pregnancy outcome; these are based on the l imited available evidence and our own experience.
Preventing maternal thrombotic complications
Warfarin crosses the placenta and is teratogenic in the first trimester of pregnancy so low molecular weight heparins are the agents of choice for antenatal thromboprophylaxis.
14 26
Observational studies have shown that low molecular weight heparin is at least as effective as unfractionated heparin and safer. 14 26 Women who are on long term warfarin because of previous thrombosis should switch to heparin when trying to conceive or on confirmation of conception. The dose of heparin will depend on the woman's clinical history and should be discussed with a haematologist.
Preventing adverse pregnancy outcome A meta-analysis of intervention trials for recurrent (early) miscarriage have concluded that heparin with low dose aspirin reduces pregnancy loss by 54%. 27 No randomised controlled trials have investigated prevention in patients with a history of late miscarriage, fetal death, and intrauterine growth restriction. Most clinicians would consider treatment with low dose aspirin and heparin (mostly low molecular weight heparin) in such cases. In patients with antiphospholipid antibodies and a history of severe preeclampsia at least low dose aspirin (75-80 mg once daily) is recommended.
18
Glucocorticoids, cytotoxic agents, and intravenous immunoglobulin have no confirmed benefit and may even be teratogenic.

Systemic lupus erythematosus
In patients with SLE and antiphospholipid antibodies, low dose aspirin may be considered for primary pr evention of thrombosis and pregnancy loss. 28 In non-pregnant patients with SLE and antiphospholipid syndrome associated thrombosis, long term anticoagulation with vitamin K antagonists is effective for secondary prevention of thrombosis. In pregnant patients with SLE and antiphospholipid syndrome, combined unfractionated heparin or low molecular weight heparin and aspirin reduce pregnancy loss and thrombosis and should be considered.
28
Catastrophic antiphospholipid syndrome Box 2 summarises the management and characteristics of this rare manifestation of the syndrome.
Future challenges for management
A reliable diagnostic test is still needed. Antiphospholipid syndrome mimics many other conditions, which leads to misdiagnosis and thwarts efforts to perform studies of sufficient size to give unequivocal support for diagnostic and treatment strategies. However, left untreated the syndrome can have serious sequelae. We advise that any patient with a suspected antiphospholipid syndrome should be seen by a multidisciplinary team of specialists that ideally includes a rheumatologist, haematologist, neurologist, nephrologist, and obstetrician for diagnosis, treatment, and education.
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